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Antigenic profiles of post-2002 H5N1 viruses representing major genetic clades and various geographic sources
were investigated using a panel of 17 monoclonal antibodies raised from five H5N1 strains. Four antigenic groups
from seven clades of H5N1 virus were distinguished and characterized based on their cross-reactivity to the
monoclonal antibodies in hemagglutination inhibition and cell-based neutralization assays. Genetic polymorphisms
associated with the variation of antigenicity of H5N1 strains were identified and further verified in antigenic
analysis with recombinant H5N1 viruses carrying specific mutations in the hemagglutinin protein. Modification of
some of these genetic variations producedmarked improvement to the immunogenicity and cross-reactivity of H5N1
strains in assays utilizing monoclonal antibodies and ferret antisera raised against clade 1 and 2 H5N1 viruses,
suggesting that these sites represent antigenically significant amino acids. These results provide a comprehensive
antigenic profile for H5N1 virus strains circulating in recent years and will facilitate the recognition of emerging
antigenic variants of H5N1 virus and aid in the selection of vaccine strains.
In 2003 human H5N1 infections reemerged in China follow-
ing the first documented cases in 1997 (11, 32, 43, 57, 58).
Subsequently, poultry outbreaks were observed across multiple
countries in Southeast Asia (27, 42, 52). Surveillance studies of
both chicken and duck in southern China showed that H5N1
virus had persisted in poultry and continued to circulate in
waterfowl since 1998 (6, 7, 14), causing repeated outbreaks in
chicken, possibly in the process of adapting to land-based poul-
try (27, 42). Genetic analysis indicates that after 1997 the
H5N1 virus evolved into multiple genotypes (14). More re-
cently, these multiple genotypes had been replaced by a single
dominant strain, H5N1 genotype Z (27), that has caused out-
breaks throughout Asia with sporadic transmission to humans
(42, 52). The outbreak in migratory birds at Qinghai Lake,
China, in early 2005 led to further expansion of the geograph-
ical distribution of H5N1 virus from Asia to Europe, the Mid-
dle East, and Africa (9, 12, 29, 36). It is recognized that the
long-term endemicity of H5N1 virus in poultry has generated
genetically and antigenically diversified viruses in some coun-
tries (8, 41). The unprecedented persistence of H5N1 virus in
poultry since 1996 and continued human infection observed in
multiple affected countries since 2003 have raised the concern
that this virus might spark a pandemic.
It is uncertain when another influenza pandemic may occur
and even difficult to determine whether the current global
spread of H5N1 virus is a false alarm or an indication of
another pandemic in the making. In preparation for the worst
scenarios, it is believed an effective vaccine will be vital to
alleviating the next pandemic. However, it is also anticipated
that a vaccine may not be available until several months after
a pandemic strain is identified. Several complicating factors
differentiate the development of a pandemic H5N1 vaccine
from the development of vaccines against seasonal human
influenza strains, a program now well established and largely
successful (40). First, a pandemic vaccine has never before
been developed, meaning that researchers have no prior expe-
rience on which to base their efforts. Second, unlike human
H1N1, H2N2, and H3N2 strains, the H5N1 virus causing hu-
man infections is still of the avian type (8, 27, 41, 54, 55), for
which an epidemiological model for antigenic prediction has
not been established (39). It is also not clear whether genetic
variations in the hemagglutinin (HA) protein are a result of
immune escape or associated with host adaptation (54). It
would therefore be difficult to predict the likely match of H5N1
vaccines without understanding the antigenic determinants of
H5N1 viruses. Two antigenic sites corresponding to sites A and
B of the H3 subtype of the HA molecule were recently de-
scribed by characterizing antibody escape mutants of a recom-
binant virus containing the HA and neuraminidase (NA) genes
of A/Vietnam/1203/04 (A/VNM/1203/04), a clade 1 virus, in
the background of A/Puerto Rico/8/34 (H1N1) virus (21). Ge-
netic studies based on phylogenetic analysis of the HA gene
have revealed that at least 10 clades of H5N1 viruses have
emerged since 2000 (8, 36, 41, 52, 53). However, there has not
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been a systematic comparison of antigenicity between these
genetic variants.
A comprehensive characterization of the antigenicity of H5N1
viruses isolated from the time when human infections reemerged
in 2003 until the present is necessary to understanding the anti-
genic evolution of H5N1 viruses and would provide important
information for vaccine selection. In this study, we developed a
panel of more than 400 monoclonal antibodies (MAbs) that react
with a wide range of H5N1 strains and used these antibodies to
investigate the antigenic profiles of H5N1 viruses from different
genetic lineages. Genetic polymorphisms on the HA protein were
identified that are associated with antigenic variation. Manipula-
tion of these polymorphic sites to improve immunogenicity of
H5N1 viruses was explored, with a view to determine antigenically
significant amino acids in HA protein.
MATERIALS AND METHODS
Virus propagation and titration. H5N1 viruses were grown in the allantoic
cavities of 10-day-old embryonated chicken eggs at 35°C for 48 h. The allantoic
fluid was harvested, and aliquots were stored at 80°C until use. Virus titer was
determined by calculating the 50% tissue culture infectious dose (TCID50) per
ml of virus stock, using the method of Reed and Muench (34). Experiments using
H5N1 virus were performed inside the biosafety level 3 facility at The University
of Hong Kong.
Production of H5 monoclonal antibodies. Five representative H5N1 strains,
Chicken/Hong Kong/YU22/2002 (Ck/HK/YU22/2002; clade 8), Duck/VNM/
S654/2005 (Dk/VNM/S654/2005; clade 1), Dk/Indonesia/MS/2004 (Dk/IDN/MS/
2004; clade 2.1), Barheadded goose/Qinghai/15C/2005 (BH goose/QH/15C/2005;
clade 2.2), and Dk/VNM/568/2005 (clade 2.3) were chosen as immunogens for
the preparation of anti-H5 MAbs by standard hybridoma technology (45). Based
on phylogenetic analysis, these strains were selected from the major H5N1 clades
in current circulation (clade 1, 2.1, 2.2, and 2.3) to cover the genetic and antigenic
diversities of H5N1 viruses (8, 41). A clade 8 virus, Ck/HK/YU22/02, was in-
cluded as it represents more ancestral strains isolated during an outbreak in
Hong Kong in 2002 (27). Briefly, viruses were inactivated by adding formalin to
a final concentration of 0.03%, and allantoic fluids were kept at 4°C for 72 h.
Inactivation was confirmed by the absence of detectable infectivity after two
blind passages of the treated allantoic fluids in embryonated chicken eggs. We
then emulsified 400 l of inactivated H5N1 virus, adjusted to a titer of 5  107
TCID50/ml before inactivation, with an equal volume of Freund’s complete
adjuvant, and injected the virus subcutaneously into six-week-old female BALB/c
mice at 2-week intervals. A final dose of 100 l of inactivated virus was injected
intravenously 3 days prior to fusion of spleen cells from the immunized mice with
mouse myeloma cells (SP2/0-Ag14). The resulting hybridomas were screened for
the secretion of H5-specific MAbs against Ck/HK/YU22/2002 and other non-H5
reference viruses by a hemagglutination inhibition (HI) assay, and positive clones
were expanded and cultured in 75-cm2 flasks. Cells that produced MAbs were
then cloned by limiting dilution at least three times. MAbs were prepared by
injection of hybridoma culture into the peritoneal cavities of pristine-primed
BALB/c mice; the ascitic fluid was collected after 9 to 12 days and stored at
20°C. MAbs were purified using ammonium sulfate precipitation, followed by
DE-52 ion exchange chromatography. Immunoglobulin concentrations were de-
termined by spectrophotometry using a Perkin Elmer MBA 2000 spectrometer
(Waltham, MA). Isotyping was performed by indirect enzyme-linked immu-
nosorbent assay using mouse MAb isotyping reagent (BD Biosciences, San Jose,
CA) as capture antibody and horseradish peroxidase-conjugated goat anti-mouse
immunoglobulin as a reporter antibody.
HI test. The HI test was performed to screen specific H5 MAbs and to assess
the reactivity of ferret antiserum against different H5N1 isolates, in accordance
with the World Health Organization (WHO) Manual on Animal Influenza Di-
agnosis and Surveillance (50). Ferret antisera against Dk/HN/101/04 (clade 2.3),
A/IDN/5/05 (clade 2.1), BH goose/QH/1A/05 (clade 2.2), A/VNM/1203/04 (clade
2.1), and Swan/Mongolia/244/05 (clade 2.2) were kindly provided by the WHO
Collaborating Center on the Ecology of Influenza Viruses in Lower Animals and
Birds at St. Jude Children’s Research Hospital (41, 56). All polyclonal antisera
were treated by receptor-destroying enzyme (Denka Seiken Co., Tokyo, Japan)
prior to testing. The HI test was started at a 1:40 dilution for polyclonal anti-
serum and 1:100 dilution for monoclonal antiserum and adsorbed with a 0.5%
suspension of turkey red blood cells (Lampire Biological Laboratories, PA).
Neutralization assay. Determination of endpoint neutralizing antibody titers
was performed by microneutralization assay, as previously described (22, 35).
Briefly, serial 10-fold dilutions of MAbs were mixed and incubated with virus for
2 h at 37°C, and 35 l of the mixture, containing 100 TCID50 of virus, was then
added to Madin-Darby canine kidney (MDCK) cells and allowed to adsorb for
1 h. Virus supernatant was removed and replaced with minimal essential medium
plus antibiotics. The H5N1 virus-infected MDCK cells were incubated for 72 h at
37°C in the presence of 5% CO2, and the neutralizing titer was determined by
HA test. For the HA test, 50 l of 0.5% turkey red blood cells (Lampire
Biological Laboratories, Pipersville, PA) was added to 50 l of cell culture
supernatant and incubated at room temperature for 30 min. The neutralization
titer was the lowest MAb dilution that was negative for hemagglutination.
Generation of recombinant viruses. A/VNM/1194/04 and Chinese pond heron/
HK/18/05 (CP heron/HK/18/05) viral RNAs were extracted using a QIAamp
Viral RNA Mini Kit (Qiagen, Valencia, CA), according to the manufacturer’s
instructions. Full-length viral RNA segments were amplified using reverse tran-
scription-PCR with segment-specific primers, as described elsewhere (18), and
cloned into the pHW2000 vector, kindly provided by Eric Hoffmann of St. Jude
Children’s Research Hospital (17). Plasmids were sequenced to confirm that no
mutations were introduced during the cloning procedure. Specific changes to the
HA amino acid sequences of A/VNM/1194/04 and CP heron/HK/18/05 strains,
described in Table 3, were introduced by site-specific mutagenesis (Stratagene,
La Jolla, CA) and confirmed by sequencing. Recombinant viruses (rc-VNM/
1194/04-6a, rc-VNM/1194/04-189, and rc-CP heron/HK/18/05) and their parental
prototype viruses were generated by transfecting eight plasmids into mixed
MDCK and 293T cells, as described previously (17), using a TransIT LT-1 kit
(Mirus, Madison, WI). Recombinant viruses were rescued, and viral sequences
were confirmed. HI and neutralization tests with recombinant viruses were car-
ried out as described above.
Phylogenetic analysis and molecular characterization. Sequence assembly,
editing, alignment, and residue analysis of the HA1 gene were performed as
previously described (8). A neighbor-joining amino acid tree was constructed in
MEGA 3.1 using the Jones-Tayler-Thornton amino acid replacement model with
1,000 bootstrap replicates (24).
RESULTS
Grouping of H5 MAbs. Over 400 H5 MAbs were raised
against five genetically diverse strains of the H5N1 virus. Forty-
one representative strains of H5N1 viruses were selected from
10 different genetic clades (Fig. 1), as defined by the WHO
H5N1 virus evolution working group (53), and used to char-
acterize the MAbs by HI testing. A group of 17 MAbs display-
ing various reactive spectra were selected for neutralization
assay in MDCK cells (Table 1). Most of the MAbs showed
similar patterns of reactivity in both neutralization assays and
HI tests (data not shown), suggesting that they may bind to
receptor binding regions. Based on the HI test and neutraliza-
tion assay results, these MAbs were classified into three
classes, as shown in Table 1. Class I antibodies possess broad
reactive spectra and react well with almost all tested strains of
H5N1 virus in the neutralization assay. Classes II and III have
a comparatively more narrow reactive spectra, reacting with
some H5N1 virus clades but exhibiting poor or no reactivity
with other tested viruses. This panel of MAbs was used for the
antigenic characterization of H5N1 viruses described below.
Antigenic classification of H5N1 virus. Forty-one H5N1 vi-
ruses selected from current genetic clades and tested in this
study (Fig. 1) were, in turn, grouped according to their reac-
tivity to the three classes of MAbs in the cell-based neutral-
ization assay (Table 1). Group A viruses, comprised mainly of
clade 2.1 viruses isolated from Indonesia, react to most mem-
bers of the MAb classes. A clade 2.4 virus, Ck/Yunan/115/04
(Ck/YN/115/04), which is phylogenetically close to clade 2.1,
showed a similar antigenic profile to other viruses in this group
(Fig. 1). HK/213/03, a clade 1 virus in this antigenic group, has
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an HA position 223 amino acid substitution compared to other
clade 1 viruses and was reported to display a unique antigenic
feature (16, 27, 52). Group B primarily consists of clade 1
viruses, together with viruses from clades 4, 5, 7, and 9, which
share similar polymorphism patterns in the HA protein (Table
2). This group of viruses reacts with class I and II but not class
III MAbs. The antigenic similarity in viruses from different
phylogenetic clades may be the result of sharing similar char-
acteristics in the antigenic sites while maintaining their clade-
specific sequences. Group C contains clade 2.2 Qinghai-like
viruses and also viruses from clade 2.3. This group of viruses
reacts with class I and III MAbs, similar to group A viruses, but
not with class II MAbs, with the exception of 3C8 and, to a
lesser extent, 9H12B (Table 1). One Qinghai-like virus isolated
in 2006, Guinea fowl/Shantou/1341/06 (Gf/ST/1341/06) (41),
showed no obvious difference in antigenicity to the Qinghai
virus, BH Goose/QH/15/05, which was first isolated in early
2005 during the initial outbreak (9). Group D is composed
almost exclusively of clade 2.3.4 Fujian-like viruses from the
highly diverse clade 2.3 (Table 1 and Fig. 1) (41). A striking
feature of group D viruses is that they react only with class I
MAbs, displaying little or no reactivity with class II and the
majority of III MAbs except 1G2 and 16F8. As previously
reported, clade 2.3.4 viruses became prevalent in China from
late 2005 onwards and were subsequently detected in Hong
Kong, Laos, Malaysia, Thailand, and Vietnam (1, 10, 41).
These viruses represent one of the four distinct groups of
H5N1 viruses that are currently circulating, in addition to the
Qinghai-like viruses (clade 2.2) (9, 12, 29, 36) and those in
Indonesia (clade 2.1) and Vietnam (clade 1) (42, 52). Two
clade 2.3 group D viruses, CP heron/HK/18/05 and Dk/Hunan/
101/04 (Dk/HN/101/04) (8), showed very poor reactivity to
most of the three classes of MAbs tested. The four antigenic
groups defined here by MAbs are largely related to their phy-
logenetic classification (Fig. 1), with four major currently cir-
culating clades falling into distinct antigenic groups (Table 1).
It appears that the currently circulating clade 2 viruses are
more antigenically diverse than other clades. The distinct an-
tigenic features of group D viruses indicate that a major drift
may have occurred.
Genetic polymorphisms and antigenic variation. To under-
stand the molecular basis of the antigenic variation of H5N1
viruses, genetic mutations on the HA protein were analyzed.
Table 2 shows the clusters of genetic polymorphisms iden-
tified among groups A, B, C, and D viruses. These genetic
polymorphisms reflect the antigenic patterns revealed by
MAb analysis (Table 1). Nine HA polymorphisms (amino
acid residues 86, 94, 124, 129, 138, 140, 189, 212, and 263)
were identified in the majority of group B H5N1 viruses
(Table 2). Polymorphisms in group C were differentially
distributed between clades 2.2 and 2.3; furthermore, the
clade 2.3 viruses in group C carry mutations that are also
prevalent in group D viruses. However, consistent with their
distinct antigenic pattern, group D H5N1 viruses had 11
(amino acid residues 140, 155, 156, 174, 181, 189, 227, 269,
282, 310, and 322) genetic polymorphisms (Table 2). Based
on the HA structure of H5N1 virus (15, 38), the majority of
the polymorphic sites identified in Table 2 are exterior res-
idues in the HA protein, except for 94, 174, and 263 that are
in interior positions and not shown (Fig. 2). It remains to be
investigated if those interior residues may contribute to
antibody binding.
Taken together, genetic data demonstrate that each of the
four antigenic groups of H5N1 virus carry distinct patterns of
polymorphism in the HA molecule. Interestingly, many of the
mutations listed in Table 2 are potential antigenic sites similar
to the mapping of H3N2 virus antigenic structure (22, 49).
Detailed characterization with MAbs is necessary to confirm
the antigenic function of these sites.
Genetic polymorphisms associated with antigenicity. Two
antigenic epitopes, corresponding to sites A and B of the H3
HA molecule, have recently been described in a recombi-
nant virus containing the HA and neuraminidase of
A/VNM/1203/04, but other antigenic sites are less clear (21).
Similar genetic polymorphisms were observed within the
group B viruses characterized in this study (Tables 1 and 2).
To investigate if the polymorphic regions/sites identified in
Table 2 are in fact associated with the altered immunoge-
nicity of H5N1 viruses, we first selected group-specific mu-
tations for site-directed mutagenesis. A neutralization assay
showed that both group B and D viruses poorly reacted with
class III MAbs (Table 1). One of the group B H5N1 viruses,
VNM/1194/04, which has been well studied and recom-
mended by WHO in the first group of prepandemic vaccine
strains (2), was used to address this question. There are
seven amino acid polymorphisms in VNM/1194/04 virus HA,
and the majority of these positions correspond to antigenic
epitopes as described in H3N2 human influenza virus (49).
Most group B and D viruses, which demonstrated poor
reactivity with class III MAbs, have a 189-Lys polymorphism
compared to group A and C viruses.
Based on genetic polymorphism in the group B H5N1
viruses, two recombinant viruses were derived from VNM/
1194/04 virus by site-directed mutagenesis: rc-VNM/1194/
04-6a with six mutations at amino acid residues 86 (site E),
124 (site B), 129 (receptor binding site [RBS]), 189 (site B),
212 (site D), 263 (site E); and rc-VNM/1194/04-189 with a
single mutation at residue 189 (Table 3). These site-directed
mutations changed the residues to the consensus sequences
of isolates shown in Tables 2 and 3. The recombinant HA
genes were reconstituted into viruses together with the
seven other parental segments using reverse genetic tech-
FIG. 1. Phylogenetic tree built with HA amino acid sequences illustrating the phylogenetic clades of viruses used in this study. Clades of H5N1
virus were classified according to recommended nomenclature of the WHO evolution working group, e.g., 2.1 indicates 2003 to 2007 from
Indonesia (mixed avian/human). A detailed description of each clade is provided at the WHO website (53). A, B, C, and D represent four antigenic
groups of H5N1 viruses characterized in this study with MAbs (Table 1) and are highlighted in blue, orange, green, and purple, respectively. Clade
2.3.4 was specified as it was also called “FJ-like” virus previously (41). Isolates of H5N1 virus used for generating monoclonal antibodies are labeled
in a blank box. Abbreviations: Env, environment; FJ, Fujian; GD, Guangdong; Gs, goose; GX, Guangxi; GY, Guiyang; JX, Jiangxi; MDk, migratory
duck; MYS, Malaysia; Ph, pheasant; Qa, quail; Rb pochard, rosybilled pochard; SCk, silky chicken; SZ, Shenzhen; THA, Thailand.
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nology (17). The neutralization assay demonstrated that re-
activity with MAbs was improved in rc-VNM/1194/04-6a
(Table 4). Virus rc-VNM/1194/04-6a showed higher reactiv-
ity with all class III MAbs and most class II MAbs in com-
parison to the group B prototype virus VNM/1194/04. In
contrast, rc-VNM/1194/04-189 showed no significant im-
provement in reactivity to the prototype virus in any of three
MAb classes. This suggests that 189-Lys alone has little
effect on antigenic variation in group B viruses. However, it
remains to be investigated if interaction between HA resi-
TABLE 2. Genetic polymorphism of HA gene of H5N1 virus
Group Virusa Clade
Residue at the indicated antigenic site and positionb:
Site
E
Site
B RBS
Site
A
Site
B Glyco
Site
B
Site
D
Site
E
Site
C
86 94 124 129 138 140 155 156 174 181 183 189 212 227 263 269 277 282 310 322
A Ck/HK/YU22/02 8 A D N S Q K S S V P D R K E A L K M R Q
Ck/IDN/2A/04 2.1 A N D S Q K S T V P D R K E A L K M R Q
Dk/IDN/MS/04 2.1 A N D S Q K S A V P D R K E A L K M R Q
Ck/Salatiga/BBVet-
IV/05
2.1 A N D S L R S S V P D R K E A L K M R Q
Ck/Malang/BBVet-
IV/04
2.1 A N N S Q K S A V P D R K E A L K M R Q
HK213/03 1 A D S L Q K N A V P D R K E A L K M R Q
Ck/Bantul/BBVet-I/05 2.1 A N D S Q K S T V P D R K E A L K M R Q
Ck/YN/115/04 2.4 A N D S L R S S V P D R K D A L K V R Q
B Gs/GX/2112/04 5 A D N S Q R S A V P D K K E A L K M R Q
Ck/Jogjakarta/BBVet-
IX/04
2.1 A S D S L R S T V P D K K E A L K M R Q
Dk/Vietnam/283/05 1 V D S L Q R S T I P D R R E T L K M R Q
Dk/HK/821/02 1 A D S L Q K S A V P D R K E A L K M R Q
Ck/Malaysia/5858/04 1 V D S L Q K S T V P D K R E T L K M R Q
VNM/1194/04 1 V D S L Q K S T V P D K R E T L K M R Q
VNM/1203/04 1 V D S L Q K S T V P D K R E T L K M R Q
Dk/VNM/N-XX/04 1 V D S L Q K S T V P D K R E T L K M R Q
Dk/VNM/S654/05 1 V D S L Q K S T V P D K R E T L K M R Q
MDk/JX/1653/05 9 A D N S L K S A V P D K K E A L K M R Q
Dk/Fujian/897/05 9 A D N S L K S A V P D K K E A L K M R Q
Gs/GY/337/06 4 A D N L L E S S V P D K T E A L K M R Q
Gs/YN/5539/05 7 A D N L L K N T V P D K K E A L K M R Q
C IDN/5/05 2.1 T S D S L S S T V P D R K E A L K M R Q
BH goose/QH15/05 2.2 A N D S Q R N A V P D R K E T L K I R Q
Gf/ST/1341/06 2.2 A N D S Q R N A V P D R K E T L K I R Q
MDk/JX/2295/05 2.2 A N D S Q R N A V P D R K E T L K I R Q
Ck/HN/999/05 2.3 V N D S Q K N A V P D R K D A V K M K Q
Dk/HN/157/05 2.3 V N D S Q K N A V P D R K D A V K M K Q
Ck/ST/4231/03 2.2 A N D S Q R S T V P D R K E A L K I R Q
Dk/GX/951/05 2.3 A N D L Q S N A V P D R K D A V K M K Q
Dk/HN/1265/05 2.3 A N D L Q S N A V P D R K D A V K M K Q
D Ck/GX/2439/04 5 A D N S Q R S A V P D K R X A L K M R Q
Qa/Gx/575/05 2.3 A N D L Q S N A V P D R K D A V K M K Q
Common Magpie/HK/
645/2006
2.3 A N D S Q T N T I S D K K D A V K I K L
Oriental Magpie Robin/
HK/366/2006
2.3 A N D S Q T N T I S D K K D A V K I K L
Ck/HK/282/2006 2.3 A N D S Q T N T I S D K K D A V K I K L
White eye/HK/737/07 2.3 A N D S Q T N T I S D K K D A V K I K L
SZ/406H/2006 2.3 A N D S Q T N T I S D K K D A V K I K L
Dk/VNM/568/05 2.3 A N D L Q N D A V P D R K D A V K M K Q
Peregrine-falcon/HK/
1143/07
2.3 A A N L Q N S A V P D R K D T V R M R Q
Dk/HN/101/04 2.3 A N D S Q K N A V P D R K D A V K M K Q
CP heron/HK/18/05 2.3 A N N V Q S N A V P N M K D A V R M K Q
Consensus A N D S Q K S V P D R K E A L K M R Q
a Abbreviations: FJ, Fujian; GD, Guangdong; Gs, goose; GX, Guangxi; GY, Guanyang JX, Jiangxi; MDk, migratory duck; MYS, Malaysia; Qa, quail; Rb pochard,
rosybilled pochard; SCk, silky chicken; SZ, Shenzhen (see also text); Glyco, glycosylation.
b The amino acid residue positions are derived from mature H5 sequence. Residues in boldface indicate polymorphisms in the HA sequence of the H5N1 viruses
compared with the consensus sequence.
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due 189 and the other five amino acids examined in this
study may be important for antibody binding (5, 22, 49).
HI (data not shown) and neutralization assays (Table 1)
showed that CP heron/HK/18/05 (group D) reacted poorly with
virtually all MAbs used in this study, which provides a good
prototype for investigating the association of genetic mutations
and antigenic variation in H5N1 virus. Comparison of the HA
sequence of this virus with consensus sequences of other H5N1
viruses revealed that CP heron/HK/18/05 carried 10 mutations
against the consensus (Table 2). Among them, 129-Val, 183-
Asn, and 189-Met are unique mutations and found only in CP
heron/HK/18/05, while 277-Arg was shared with just a single
virus (Table 2). Mutations at positions 129 and 189, but with
different amino acid residues, were also seen in VNM/1194/04
(Table 2).
We then examined if these four polymorphisms at positions
129, 183, 189, and 277 might contribute to the loss of reactivity
of CP heron/HK/18/05 to class I, II, and III MAbs (Table 1).
Antigenic tests with recombinant virus (rc-CP heron/HK/18/
05) in both the HI test (data not shown) and neutralization
assay (Table 4) showed marked improvement in reactivity with
all class I and most class III MAbs but no obvious improve-
ment against class II MAbs, suggesting that the targeted ge-
netic variations are associated with the binding sites of class I
and III MAbs.
Ferret antiserum has been commonly used for the evalu-
ation of influenza virus antigenicity (40, 51, 52). The HA-
modified recombinant derivatives of rc-VNM/1194/04 and
rc-CP heron/HK/18/05 were tested for reactivity to antisera
raised against different H5N1 strains (Table 5). Both HA-
modified rc-VNM/1194/04 and rc-CP heron/HK/18/05 exhib-
ited improved reactivity to a panel of ferret antisera over
that of their parental strains in the HI test. More impor-
tantly, both HA-modified recombinant H5N1 strains cross-
react with reference ferret serum raised against clade 1 and
2 H5N1 viruses. The broad cross-reactivity of the HA-mod-
ified strains to antiserum raised against antigenically differ-
ent strains demonstrates the contribution of these genetic
mutations to the lack of cross-clade antigenic reactivity
among antigenically diverse H5N1 viruses. Taken together,
these results demonstrate that the HA polymorphisms iden-
tified in this study are associated with H5N1 virus antige-
nicity and that manipulation of these sites may improve viral
immunogenicity.
FIG. 2. Ribbon diagram of the trimeric HA molecule with the
mutations shown as yellow spheres. The majority of the polymorphic
sites (Table 2) are exterior residues, with the exception of residues 94,
174, and 263 (not shown). The RBS is indicated with a blue oval. The
reference monomer is drawn in color, and the other two monomers are
shown in gray. In the reference monomer, polypeptide HA1 is in red,
polypeptide HA2 is in blue, and the polysaccharides are drawn in
ball-and-stick form in green. The diagram was prepared with the pro-
gram MOLSCRIPT (23) and Raster3D (30).
TABLE 3. Amino acid residue positions in the HA gene selected
for site mutagenesis
Virus
Residue at amino acid positiona:
86 124 129 183 189 212 263 277
VNM/1194/04 V S L D K R T K
rc-VNM/1194/04-6a A D S D R K A K
rc-VNM/1194/04-189 V S L D R R T K
CP heron/HK/18/05 A N V N M K A R
rc-CP heron/HK/18/05 A N S D R K A K
a Mutated amino acid residues are in boldface.
TABLE 4. Comparison of antigenicity of recombinant viruses in neutralization assay using MAbs
Virus
Neutralization titer of the indicated MAb by classa
I II III
20A11 16F13 13D4 16G3 14E4 20H2 3C8 9H12B 16A12 14D4 1G2 3F1B8 16F8 4GE1 1D8 6CF3 10DD2
VNM/1194/04 12,800 3,200 12,800 12,800 6,400 12,800 1,600 1,600 1,600        
rc-VNM/1194/04-6a 12,800 12,800 12,800 12,800 12,800 12,800 12,800 1,600 12,800  12,800 12,800 12,800  3,200 12,800 12,800
rc-VNM/1194/04-189 12,800 12,800 12,800 12,800 12,800 12,800 12,800 400  200 200      
CP heron/HK/18/05       100 800  12,800 12,800 1,600 100    1600
rc-CP heron/HK/18/05 12,800 12,800 12,800 12,800 12,800 12,800 3,200 200  12,800 12,800 12,800 12,800 400 12,800 12,800 12,800
a Same panel of MAbs as in Table 1. rc, recombinant; , 100.
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DISCUSSION
Antigenic drift of influenza virus is caused by an accumula-
tion of mutations in the epitope regions of the HA to which
neutralizing antibodies bind (38, 46, 49). Drift on viral surface
proteins, mainly the HA, allows the virus to evade antibody
binding within the host (40, 46). Prediction of antigenic drift is
a factor in determining if a vaccine will match the circulating
strain (3, 40). Though highly pathogenic avian influenza H5N1
virus has been continuously circulating for more than a decade
in Asia, antigenic drift in H5N1 viruses has not been fully
evaluated. The current understanding of influenza virus anti-
genic drift is based solely on the analysis of the cartography of
human H3N2 and H1N1 influenza viruses, which are under the
selection of population-level immunity (4, 31, 39, 47, 49). Un-
like human influenza virus subtypes, H5N1 viruses have circu-
lated only in domestic and wild birds to date (48). Avian in-
fluenza viruses are thought to maintain a stable antigenic and
nonpathogenic status in their natural hosts, wild aquatic birds
(46). Poultry has a relatively short life span, and massive sea-
sonal vaccinations of poultry against avian influenza virus are a
recent development (25, 33). In unvaccinated aberrant hosts,
such as chicken, infection with highly pathogenic H5N1 virus is
lethal (13, 20, 37). Thus, accumulation of mutations on the HA
of avian influenza virus may not be caused by continuous an-
tibody selection, as has occurred with human influenza viruses.
Alteration of receptor binding specificity by introducing muta-
tions onto avian H5 influenza HA also caused changes in virus
immunogenicity (55), making it unclear if the model for H3N2
would apply for H5N1 viruses (40). Therefore, a working
model for predicting the antigenicity of H5N1 virus is neces-
sary in preparation for a potential pandemic (39).
The traditional approach using antisera raised from immu-
nized ferrets provided a gold standard for evaluating antigenic
changes to human influenza viruses (40), and a similar meth-
odology was adopted for H5N1 virus, as recommended by the
WHO (8, 12, 41, 52). Antiserum must be updated with newly
circulating strains and then used to characterize emerging an-
tigenic variations. Cocirculation of multiple antigenic variants
of H5N1 virus hampers the timely production of standard
antiserum for antigenic analysis. The highly pathogenic and
avian features, including an avian-type receptor binding pref-
erence, of H5N1 virus also increase the difficulty of generating
H5N1-specific ferret antisera (56). MAbs have been used for
identifying antigenic epitopes on the HA of influenza virus but
less commonly for antigenic profiling because each antibody
binds only to a single epitope (5, 19, 21). This study evaluated
the use of a group of 17 MAbs selected from a large panel of
400 clones that may provide an alternative for antigenic pro-
filing of H5N1 viruses, in addition to the traditional practice of
using subtype-specific ferret antiserum. With this approach, a
newly emerged antigenic variant can be characterized before a
ferret antiserum is available. More importantly, as each MAb
maps to a specific epitope, this approach can also provide
information on genetic variations that may be associated with
antigenic change.
Consistent with our previous genetic analysis, antigenic pro-
filing with MAbs demonstrated that H5N1 virus has undergone
rapid antigenic changes since 2003 (8, 27, 41). Three antigeni-
cally distinct groups (A, C, and D) of H5N1 viruses are com-
posed mainly of clade 2 viruses, which are currently cocircu-
lating in broad regions and have evolved into several
genetically distinct subclades (53). H5N1 viruses in the same
phylogenetic group generally share similar antigenic properties
in cell-based neutralization experiments, with some exceptions.
While the majority of clade 2.1 viruses are antigenically clas-
sified as group A (Table 1), Ck/Jogiarkarta/BBVet-lX/04 and
IDN/5/05 were classified in groups B and C, respectively (Table
1). The different antigenic features of viruses in the same
genetic clade may be the result of limited mutations in the an-
tigenically important amino acids. This may also explain the
classification of some clade 2.3 viruses in group C with clade
2.2 viruses (Fig. 1). Virus phylogeny also does not correlate
with antigenic properties in group B, which includes viruses
from five different genetic clades (Table 1). It is interesting that
viruses in group D, which represent a dominant genetic variant
(clade 2.3.4) in southern China, showed a distinctive antigenic
profile that may imply a major antigenic drift has occurred. It
remains to be seen if the recent development of large-scale
vaccination of poultry in some Asian countries has contributed
to this phenomenon (33).
A broadly cross-protective vaccine for antigenic variants of
H5N1 virus will be a very important component in strategizing
prepandemic-strain vaccine development. Several vaccine
strains derived from clade 1 viruses, which are currently under
TABLE 5. Comparison of antigenicity of recombinant viruses in HI test using ferret antiseruma
Virus
HI titer of the indicated virus in ferret antiserum:
Dk/HN/101/04
(clade 2.3)
BH goose/
QH/1A/05
(clade 2.2)
IDN/5/05
(clade 2.1)
VNM/1203/04
(clade 1)
Swan/Mongolia/244/05
(clade 2.1)
Dk/HN/101/04 640 2,560 1,280 80 320
BH goose/QH/1A/05 320 640 640 40 320
IDN/5/05 80 320 1,280 40 40
VNM/1203/04 80 80 160 160 40
CP heron/HK/18/05 80 80 80 40 40
rc-CP heron/HK/18/05 320 1,280 1,280 80 160
VNM/1194/04 40 40 80 80 40
rc-VNM/1194/04-6a 320 640 1,280 80 80
rc-VNM/1194/04-189 80 160 640 80 40
a Values in italics are HI titers with homologous H5N1 strains which were used to generate ferret antiserum. Viruses and values in boldface are genetically modified
H5N1 viruses described in this study and their respective HI titers.
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different stages of clinical trials, showed limited cross-clade
reactivity (2, 28, 44). Application of adjuvant was shown to
improve immunogenicity and induce cross-reactive immunity
by A/VNM/1194/04 H5N1 (clade 1) pandemic-virus vaccine
(26). On the other hand, additional H5N1 vaccine viruses se-
lected from clade 2 have been recommended by WHO for the
development of prepandemic-strain vaccines in response to the
rapid evolution of H5N1 virus and the cocirculation of multiple
antigenic variants in multiple regions (51). However, there is a
lack of data showing that these strains will provide desirable
cross-protection between antigenically distinctive clade 1 and
increasingly diversified clade 2 H5N1 viruses. This study char-
acterized the clusters of genetic polymorphisms associated with
the antigenic variations of H5N1 viruses to in vitro neutraliza-
tion reactivity of MAbs. Modification of some of the genetic
variations brought about drastic improvements to antigenic
reactivity of two H5N1 strains in assays utilizing both MAbs
and ferret antiserum, suggesting that these amino acids may
associate with antigenic sites. Further mapping of these sites
with those MAbs is necessary. It is important to investigate
whether these modified HAs may serve as better immunogens
in inducing broad cross-neutralizing antibodies in animal mod-
els. As H5N1 viruses are still of avian type, it would also be
necessary to evaluate if these sites are recognized by human
antibodies. Recent studies using recombinant H5N1 virus with
altered receptor binding specificity to human-type receptors
elicited more effective neutralizing MAbs that inhibit such
variants (16, 54, 55). Therefore, it may be worthwhile to ex-
plore the vaccine potential of H5N1 HA with alterations of
both receptor binding affinity and antigenically significant
amino acids in a virus-like particle system.
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